Haemonetics Corporation (HAE)

Strength Seen in Haemonetics (HAE): Can Its 17.5% Jump Turn into More Strength?

Is Haemonetics Corp (HAE) Overvalued After 17.5% Rally? GF Value Says Overvalued

Phase 3 Study Results Highlighting Deucrictibant's Rapid and Sustained Efficacy in Treating HAE Attacks Published in The Lancet

Haemonetics shares jump as CSL sets 2027 rollout of plasma devices

Haemonetics Stock Surges as Plasma Deal Opens Door to More Revenue

PAHC vs. HAE: Which Stock Is the Better Value Option?

Real-World Analysis Highlighting HAE Disease Experience and Gaps in Treatment Satisfaction Published in Advances in Therapy

Haemonetics Sets Date for Publishing Second Quarter Fiscal Year 2027 Results: November 5, 2026

Analyzing Haemonetics (NYSE:HAE) and Femasys (NASDAQ:FEMY)

Haemonetics (HAE) is a Top-Ranked Momentum Stock: Should You Buy?

Intellia Eyes Lonvo-z Launch as HAE PDUFA Nears, TTR Study Advances

PAHC vs. HAE: Which Stock Should Value Investors Buy Now?

Orchestra BioMed Receives $6.1 Million Milestone Payment from Acquisition of Vivasure by Haemonetics

FDA Accepts & Gives Priority Review to Intellia's BLA for HAE Drug

Intellia Therapeutics Announces FDA Acceptance of Biologics License Application with Priority Review for Lonvoguran Ziclumeran (Lonvo-z) for Hereditary Angioedema (HAE)

Pharvaris Announces Positive Topline Data from CHAPTER-3 Pivotal Study of Deucrictibant XR for Prophylaxis of HAE Attacks

GEHC vs. HAE: Which Stock Is the Better Value Option?

BioCryst Pharmaceuticals: Owning Both Sides Of The HAE Preference Curve

BioCryst Announces Approval of ORLADEYO® for Pediatric HAE Patients in Japan

4 Gene-Editing Biotech Stocks Worth Watching for Long-Term Gains